La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sirio Pharma Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Sirio Pharma ha un patrimonio netto totale di CN¥2.5B e un debito totale di CN¥1.2B, che porta il suo rapporto debito/patrimonio netto a 47.2%. Le sue attività totali e le sue passività totali sono rispettivamente CN¥5.2B e CN¥2.7B. L'EBIT di Sirio Pharma è CN¥455.6M rendendo il suo rapporto di copertura degli interessi 5.3. Ha liquidità e investimenti a breve termine pari a CN¥585.5M.

Informazioni chiave

47.2%

Rapporto debito/patrimonio netto

CN¥1.18b

Debito

Indice di copertura degli interessi	5.3x
Contanti	CN¥585.53m
Patrimonio netto	CN¥2.49b
Totale passività	CN¥2.68b
Totale attività	CN¥5.17b

Aggiornamenti recenti sulla salute finanziaria

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Jun 12

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06

Recent updates

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CN¥1.9B ) di 300791 superano le sue passività a breve termine ( CN¥751.4M ).

Passività a lungo termine: Le attività a breve termine di 300791 ( CN¥1.9B ) non coprono le sue passività a lungo termine ( CN¥1.9B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 23.7% ) di 300791 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 300791 è aumentato da 24.4% a 47.2% negli ultimi 5 anni.

Copertura del debito: Il debito di 300791 è ben coperto dal flusso di cassa operativo ( 30.7% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 300791 sono ben coperti dall'EBIT ( 5.3 x copertura).

Sirio Pharma Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Recent updates

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Now 21% overvalued

Now 21% overvalued

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investor sentiment deteriorates as stock falls 27%

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Price target increased by 7.8% to CN¥41.67

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 22% undervalued

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

Investor sentiment deteriorated over the past week

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥89.00

Sirio Pharma Co., Ltd. announced a financing transaction

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane